Valvuloplasty as Alternative to Toupet Fundoplication for GERD (VANTAGE)
Primary Purpose
Gastroesophageal Reflux, Hernia, Hiatal
Status
Withdrawn
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Laparoscopic gastroesophageal valvuloplasty
Laparoscopic Toupet fundoplication
Sponsored by
About this trial
This is an interventional treatment trial for Gastroesophageal Reflux focused on measuring Valvuloplasty, Fundoplication, Acid reflux, GERD, Reflux disease, Hiatal hernia
Eligibility Criteria
Inclusion Criteria:
- Objectively proven GERD (by gastroscopy and/or 24-hour pH and/or impedance monitoring)
- Age ≥18
- Written informed consent for study participation
Exclusion Criteria:
- BMI ≥ 30
- Hiatal hernia >3cm
- Achalasia
- Previous gastric surgery
- Previous esophageal surgery
- Inability to understand the Dutch language
- Inability to understand and/or fill in the questionnaires
Sites / Locations
- Meander Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Laparoscopic valvuloplasty
Laparoscopic Toupet fundoplication
Arm Description
Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
Outcomes
Primary Outcome Measures
Success rate, objective
Defined as % of patients with normal values of reflux measured by pH and impedance monitoring
Secondary Outcome Measures
Success rate, subjective
Defined as % of patients with Visick score I or II
Percent of patients with complaints of functional dysphagia according to the Rome III criteria
% of patients with complaints of functional dysphagia according to the Rome III criteria.
Cost-effectiveness
Cost-effectiveness will be calculated by comparing the direct and indirect medical cost related to both strategies up until one years after the operation.
Mortality rate
Defined as in-hospital mortality or out of hospital mortality within 30 days
Complication rate
Intra-operative complication rate
Conversion rate
Disease related reoperation rate
% of patients requiring redo surgery for persisting complaints or recurrence
Full Information
NCT ID
NCT02625077
First Posted
November 15, 2015
Last Updated
March 23, 2017
Sponsor
Meander Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02625077
Brief Title
Valvuloplasty as Alternative to Toupet Fundoplication for GERD
Acronym
VANTAGE
Official Title
Valvuloplasty as Alternative to Toupet Fundoplication for the Minimal Invasive Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Ethical concerns with efficacy of technique.
Study Start Date
January 2016 (undefined)
Primary Completion Date
January 2019 (Anticipated)
Study Completion Date
January 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Meander Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This monocenter randomized controlled trial aims to compare postoperative outcomes of a laparoscopic valvuloplasty with a Toupet fundoplication in patients with GERD with a maximum hiatal hernia of 3cm. In addition, an economic evaluation of the new intervention will be done in order to determine cost-effectiveness and costs per quality-adjusted life-year (QALY).
Detailed Description
This is a prospective, interventional, double-blinded, monocenter randomized controlled trial comparing a laparoscopic gastroesophageal valvuloplasty to laparoscopic Toupet fundoplication in patients with proven GERD with a maximum hiatal hernia of 3cm. In this design, both patient and researcher are blinded to the treatment allocation.
Block randomization will be used to ensure an equal number in each treatment arm. Block randomization works by randomizing participants within blocks such that an equal number are assigned to each treatment. To reduce selection bias by predictability of the treatment allocation, random block sizes are used. Also the investigator is kept blind to the size of each block. A computer is used to generate 15 blocks for each participating center with random block sizes of 4, 8 and 12. Allocation proceeds by randomly selecting one of the orderings and assigning the next block of participants to study groups according to the specified sequence.
Patients will be included during a two-year period and followed for a minimum of one year. When a patient is referred to a participating surgeon for antireflux surgery, he or she will receive study information to give them sufficient time for consideration. The surgeon will ensure all required pre-operative diagnostic tests are performed and that the indication for surgery is valid. During a follow-up visit, the surgeon ascertains that the patient complies with all inclusion criteria and does not meet any of the exclusion criteria. Study participation will be discussed and after informed consent is obtained, the patient will be included in the trial.
After inclusion, the patient is immediately randomized but treatment allocation is not yet shared with the surgeon. The patient will receive validated questionnaires to record the pattern of symptoms, quality of life, medication and medical care usage. Data from the pre-operative tests will be recorded.
On the day of surgery, the surgeon will be able to see treatment allocation and after performing the appropriate surgical procedure, records the course and specifics of the surgical procedure. Patients will receive a diary to record their meals and symptoms.
Follow-up in the outpatient clinic will take place at the surgeon's discretion. At fixed moments: 3, 6 and 12 months after surgery, the patients will once more receive validated questionnaires. Also at about three months, a follow-up manometry and 24-hour pH and/or impedance monitoring will be performed.
A power analysis was performed to calculate the sample size. Our primary aim was to compare the effect of both surgical procedures. Based upon the current medical literature, the objective/subjective success rate for the laparoscopic Toupet fundoplication is around 88%. Pilot data from a retrospective cohort of patients that underwent valvuloplasty report a subjective success rate of 96%. Our hypothesis was that the gastroesophageal valvuloplasty is not inferior to the Toupet fundoplication when comparing its effects on acid control.
To prove non-inferiority of the valvuloplasty regarding acid reflux control, using a non-inferiority limit of 5%, 73 patients are required in each group. In all power calculations, a significance of 5% and power of 90% was used.
To accommodate for a loss to follow-up of up to 10 percent, a total sample size of 160 was chosen.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux, Hernia, Hiatal
Keywords
Valvuloplasty, Fundoplication, Acid reflux, GERD, Reflux disease, Hiatal hernia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Laparoscopic valvuloplasty
Arm Type
Experimental
Arm Description
Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
Arm Title
Laparoscopic Toupet fundoplication
Arm Type
Active Comparator
Arm Description
Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic gastroesophageal valvuloplasty
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Toupet fundoplication
Primary Outcome Measure Information:
Title
Success rate, objective
Description
Defined as % of patients with normal values of reflux measured by pH and impedance monitoring
Time Frame
3 months post-operative
Secondary Outcome Measure Information:
Title
Success rate, subjective
Description
Defined as % of patients with Visick score I or II
Time Frame
3 months post-operative, 1 year post-operative
Title
Percent of patients with complaints of functional dysphagia according to the Rome III criteria
Description
% of patients with complaints of functional dysphagia according to the Rome III criteria.
Time Frame
3 months post-operative, 1 year post-operative
Title
Cost-effectiveness
Description
Cost-effectiveness will be calculated by comparing the direct and indirect medical cost related to both strategies up until one years after the operation.
Time Frame
1 year post-operative
Title
Mortality rate
Description
Defined as in-hospital mortality or out of hospital mortality within 30 days
Time Frame
30 days
Title
Complication rate
Description
Intra-operative complication rate
Time Frame
During surgery
Title
Conversion rate
Time Frame
During surgery
Title
Disease related reoperation rate
Description
% of patients requiring redo surgery for persisting complaints or recurrence
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Objectively proven GERD (by gastroscopy and/or 24-hour pH and/or impedance monitoring)
Age ≥18
Written informed consent for study participation
Exclusion Criteria:
BMI ≥ 30
Hiatal hernia >3cm
Achalasia
Previous gastric surgery
Previous esophageal surgery
Inability to understand the Dutch language
Inability to understand and/or fill in the questionnaires
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Werner A Draaisma, MD, PhD
Organizational Affiliation
Meander Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ivo AM Broeders, MD, PhD
Organizational Affiliation
Meander Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Meander Medical Center
City
Amersfoort
State/Province
Utrecht
ZIP/Postal Code
3813 TZ
Country
Netherlands
12. IPD Sharing Statement
Links:
URL
http://www.meandermc.nl
Description
Meander Medical Center
Learn more about this trial
Valvuloplasty as Alternative to Toupet Fundoplication for GERD
We'll reach out to this number within 24 hrs